BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $685,000 | -37.7% | 84,855 | -41.1% | 0.01% | -25.0% |
| Q3 2018 | $1,099,000 | +33.2% | 144,000 | 0.0% | 0.01% | +33.3% |
| Q2 2018 | $825,000 | +20.1% | 144,000 | 0.0% | 0.01% | +20.0% |
| Q1 2018 | $687,000 | -2.8% | 144,000 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $707,000 | -6.4% | 144,000 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $755,000 | -5.7% | 144,000 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $801,000 | -33.8% | 144,000 | 0.0% | 0.01% | -37.5% |
| Q1 2017 | $1,210,000 | +32.7% | 144,000 | 0.0% | 0.01% | +33.3% |
| Q4 2016 | $912,000 | +29.2% | 144,000 | -10.0% | 0.01% | +20.0% |
| Q3 2016 | $706,000 | +55.5% | 160,000 | 0.0% | 0.01% | +66.7% |
| Q2 2016 | $454,000 | +0.2% | 160,000 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $453,000 | – | 160,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |